Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева; 2ФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310 yubykov@gmail.com
Список исп. литературыСкрыть список 1. Андрющенко А.В., Бескова Д.А. Терапевтические аспекты применения феварина (флувоксамина малеата) по результатам натуралистической программы Modus. Психиатрия и психофармакотерапия. 2008; 10 (3): 29–34. / Andriushchenko A.V., Beskova D.A. Terapevticheskie aspekty primeneniia fevarina (fluvoksamina maleata) po rezul'tatam naturalisticheskoi programmy Modus. Psychiatry and Psychopharmacotherapy. 2008; 10 (3): 29–34. [in Russian] 2. Беккер Р.А., Быков Ю.В. Афобазол (фабомотизол): анксиолитик, и не только (израильско-российский взгляд на проблему). Психиатрия и психофармакотерапия. 2017; 19 (4): 12–21. /Bekker R.A., Bykov Yu.V. Afobazole (fabomotizole): is it only an anxiolytic? An Israeli-Russian view of the problem. Psychiatry and Psychopharmacotherapy. 2017; 19 (4): 12–21. [in Russian] 3. Беккер Р.А., Быков Ю.В. Когнитивные нарушения при депрессиях: клиническое значение и современные возможности терапии. Психиатрия и психофармакотерапия. 2015; 17 (4): 40–5. / Bekker R.A., Bykov Yu.V. Cognitive impairment in depression: clinical significance and current treatment options. Psychiatry and Psychopharmacotherapy. 2015; 17 (4): 40–45. [in Russian] 4. Беккер Р.А., Быков Ю.В. Мемантин: возможности и перспективы применения в психиатрии (обзор современных данных). Психиатрия и психофармакотерапия. 2016; 18 (4): 42–51. / Bekker R.A., Bykov Yu.V. Memantine: a review of its use in psychiatry. Psychiatry and Psychopharmacotherapy. 2016; 18 (4): 42–51. [in Russian] 5. Беккер Р.А., Быков Ю.В. Поль Кильхольц и его вклад в мировую психиатрию. Дневник психиатра. 2016; 3: 3–6. / Bekker R.A., Bykov Iu.V. Pol' Kil'khol'ts i ego vklad v mirovuiu psikhiatriiu. Dnevnik psikhiatra. 2016; 3: 3–6. [in Russian] 6. Большакова О.О. Роль антидепрессантов в современной кардиологии. Клин. фармакология и терапия. 2012; 4 (21): 19–24. / Bol'shakova O.O. Rol' antidepressantov v sovremennoi kardiologii. Klin. farmakologiia i terapiia. 2012; 4 (21): 19–24. [in Russian] 7. Быков Ю.В., Беккер Р.А., Резников М.К. Депрессии и резистентность. Практическое руководство. М.: РИОР; ИНФРА-М, 2013. / Bykov Iu.V., Bekker R.A., Reznikov M.K. Depressii i rezistentnost'. Prakticheskoe rukovodstvo. M.: RIOR; INFRA-M, 2013. [in Russian] 8. Быков Ю.В., Беккер Р.А., Сюняков Т.С. Зипрасидон: баланс между эффектами, эффективностью и переносимостью. Психиатрия и психофармакотерапия. 2016; 18 (4): 52–62. / Bykov Yu.V., Bekker R.A., Syunyakov T.S. Ziprasidone: the past, the present and the future of an antipsychotic. Psychiatry and Psychopharmacotherapy. 2016; 18 (4): 52–62. [in Russian] 9. Винникова М.А., Козырева А.В. Возможности применения феварина (флувоксамина) в терапии аффективных нарушений, встречающихся при болезнях зависимости. Наркология. 2010; 9 (105): 69–76. / Vinnikova M.A., Kozyreva A.V. Vozmozhnosti primeneniia fevarina (fluvoksamina) v terapii affektivnykh narushenii, vstrechaiushchikhsia pri bolezniakh zavisimosti. Narkologiia. 2010; 9 (105): 69–76. [in Russian] 10. Долженко М.М. Депрессивные и тревожные расстройства в кардиологии: возможности комбинированной терапии антидепрессантом и антигипоксантом. Междунар. неврол. журн. 2013; 5 (59): 152–60. / Dolzhenko M.M. Depressivnye i trevozhnye rasstroistva v kardiologii: vozmozhnosti kombinirovannoi terapii antidepressantom i antigipoksantom. Mezhdunar. nevrol. zhurn. 2013; 5 (59): 152–60. [in Russian] 11. Дубницкая Э.Б. Опыт применения флувоксамина (феварина) при психогенных депрессиях. Психиатрия и психофармакотерапия. 2005; 7 (2): 77–8. / Dubnitskaia E.B. Opyt primeneniia fluvoksamina (fevarina) pri psikhogennykh depressiiakh. Psychiatry and Psychopharmacotherapy. 2005; 7 (2): 77–8. [in Russian] 12. Дюкова Г.М. Расстройства адаптации в медицинской практике: диагностика и терапия. Эффективная фармакотерапия. 2010; 16: 6–11. / Diukova G.M. Rasstroistva adaptatsii v meditsinskoi praktike: diagnostika i terapiia. Effektivnaia farmakoterapiia. 2010; 16: 6–11. [in Russian] 13. Иванов М.В., Сорокина А.В. Влияние фармакотерапии антидепрессантами на когнитивные функции при депрессивных расстройствах: возможности применения флувоксамина. Обозрение психиатрии и медицинской психологии им. В.М.Бехтерева. 2014; 3: 22–127. / Ivanov M.V., Sorokina A.V. Vliianie farmakoterapii antidepressantami na kognitivnye funktsii pri depressivnykh rasstroistvakh: vozmozhnosti primeneniia fluvoksamina. Obozrenie psikhiatrii i meditsinskoi psikhologii im. V.M.Bekhtereva. 2014; 3: 22–127. [in Russian] 14. Кинкулькина М.А. Лечение тяжелых эндогенных депрессий феварином (флувоксамин). Психиатрия и психофармакотерапия. 2007; 9 (4): 39–44. / Kinkul'kina M.A. Lechenie tiazhelykh endogennykh depressii fevarinom (fluvoksamin). Psychiatry and Psychopharmacotherapy. 2007; 9 (4): 39–44. [in Russian] 15. Левин Я.И., Ковальчук М.В. Депрессия и нарушения сна. Эффективная фармакотерапия. 2010; 18: 18–24. / Levin Ia.I., Koval'chuk M.V. Depressiia i narusheniia sna. Effektivnaia farmakoterapiia. 2010; 18: 18–24. [in Russian] 16. Мазо Г.Э., Незнанов Н.Г. Терапевтически резистентные депрессии. СПб., 2012. / Mazo G.E., Neznanov N.G. Terapevticheski rezistentnye depressii. SPb., 2012. [in Russian] 17. Нуллер Ю.Л. Депрессия и деперсонализация. Л.: Медицина, 1981. / Nuller Iu.L. Depressiia i depersonalizatsiia. L.: Meditsina, 1981. [in Russian] 18. Ромасенко Л.В., Шанаева И.А. Лечение расстройств сна при депрессии у пациентов с соматическими заболеваниями. Справочник поликлинического врача. 2008; 13: 58–62. / Romasenko L.V., Shanaeva I.A. Lechenie rasstroistv sna pri depressii u patsientov s somaticheskimi zabolevaniiami. Handbook for Practitioners Doctors. 2008; 13: 58–62. [in Russian] 19. Самушия М.А. Феварин (Флувоксамин) в терапии тревожно-депрессивных нозогенных реакций у пациентов с онкологическими заболеваниями. Психические расстройства в общей медицине. 2008; 1: 33–7. / Samushiia M.A. Fevarin (Fluvoksamin) v terapii trevozhno-depressivnykh nozogennykh reaktsii u patsientov s onkologicheskimi zabolevaniiami. Mental Disorders in General Medicine. 2008; 1: 33–7. [in Russian] 20. Смулевич А.Б., Ильина Н.А., Читлова В.В. Место флувоксамина в лечении депрессии в России: открытое неконтролируемое рандомизированное многоцентровое обсервационное исследование. Психиатрия и психофармакотерапия. 2016; 18 (1): 4–10. / Smulevich A.B., Ilyina N.A., Chitlova V.V. Fluvoxamine in Treatment of Depression in Russian Patients: An Open-Label Uncontrolled and Randomized Multicenter Observational Study. Psychiatry and Psychopharmacotherapy. 2016; 18 (1): 4–10. [in Russian] 21. Сюняков Т.С. Влияние флувоксамина на уровни мелатонина: обзор литературы и анализ потенциальной клинической значимости. Психиатрия и психофармакотерапия. 2014; 16 (1): 33–8. / Syunyakov T.S. Effects of fluvoxamine on the melatonin levels: literature overview and possible clinical implication. Psychiatry and Psychopharmacotherapy. 2014; 16 (1): 33–8. [in Russian] 22. Федотова А.В. Тревожно-депрессивные расстройства в общеклинической практике. Рациональная фармакотерапия в кардиологии. 2008; 3 (4): 83–90. / Fedotova A.V. Trevozhno-depressivnye rasstroistva v obshcheklinicheskoi praktike. Ratsional'naia farmakoterapiia v kardiologii. 2008; 3 (4): 83–90. [in Russian] 23. Ханнанова А.Н., Быков Ю.В., Беккер Р.А. Перспективы применения мелатонина в терапии различных психических расстройств (Обзор литературы). В мире научных открытий. 2017; 1 (9): 131–49. / Khannanova A.N., Bykov Yu.V., Bekker R.A. Perspektivy primeneniia melatonina v terapii razlichnykh psikhicheskikh rasstroistv (Obzor literatury). V mire nauchnykh otkrytii. 2017; 1 (9): 131–49. [in Russian] 24. Читлова В.В. Тревожные депрессии: аспекты психопатологии и терапии. Психиатрия и психофармакотерапия. 2012; 4: 27–33. / Chitlova V.V. Anxious depressions: aspects of psychopathology and therapy. Psychiatry and Psychopharmacotherapy. 2012; 4: 27–33. [in Russian] 25. Ширяев О.Ю., Будневский А.В., Янковская В.Л. Психосоматические аспекты терапии хронической сердечной недостаточности у больных с тревожно-депрессивными расстройствами. Прикладные информационные аспекты медицины. 2014; 1 (17): 214–20. / Shiriaev O.Iu., Budnevskii A.V., Iankovskaia V.L. Psikhosomaticheskie aspekty terapii khronicheskoi serdechnoi nedostatochnosti u bol'nykh s trevozhno-depressivnymi rasstroistvami. Prikladnye informatsionnye aspekty meditsiny. 2014; 1 (17): 214–20. [in Russian] 26. Abbas S, Chandra PS, Srivastava M. The use of fluoxetine and buspirone for treatment-refractory depersonalization disorder. J Clin Psychiatry 1995; 56 (10): 484. 27. Antipova OS, Krasnov VN, Trofimova OS. [The changes in the autonomic regulation in depressive disorders of moderate severity]. [Article in Russian]. Zh Nevrol Psikhiatr Im S.S.Korsakova 2013; 113 (11 Pt 2): 65–73. 28. Bhuiyan MS, Tagashira H, Shioda N, Fukunaga K. Targeting s1 receptor with fluvoxamine ameliorates pressure-overload-induced hypertrophy and dysfunctions. Expert Opin Ther Targets 2010; 14 (10): 1009–22. 29. Bout A, Berhili N, Benbrahim M et al. [Lamotrigine in the treatment of resistant depersonalization disorder: A case report]. [Article in French]. Encephale 2017. pii: S0013-7006(17)30113-6 30. Chen T, Tanaka M, Wang Y et al. Neurosteroid dehydroepiandrosterone enhances activity and trafficking of astrocytic GLT-1 via s1 receptor-mediated PKC activation in the hippocampal dentate gyrus of rats. Glia 2017; 65 (9): 1491–503. 31. Cobos EJ, Entrena JM, Nieto FR et al. Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr Neuropharmacol 2008; 6 (4): 344–66. 32. Dalery J, Honig A. Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison. Hum Psychopharmacol 2003; 18: 379–84. 33. Dallé E, Daniels WM, Mabandla MV. Fluvoxamine maleate normalizes striatal neuronal inflammatory cytokine activity in a Parkinsonian rat model associated with depression. Behav Brain Res 2017; 316: 189–96. 34. Dewulf L, Hendrickx B, Lesaffre E. Epidemiological data of patients treated with fluvoxamine: results from a 12 week non-comparative multicentre study. Int Clin Psychopharmacol 1995; 9 (Suppl. 4): 67–72. 35. Emmanuel NP, Lydiard RB, Crawford M. Treatment of irritable bowel syndrome with fluvoxamine. Am J Psychiatry 1997; 154 (5): 711–2. 36. Foguet Q, Alvárez MJ, Castells E, Arrufat F. Methylphenidate in depersonalization disorder: a case report. Actas Esp Psiquiatr 2011; 39 (1): 75–8. 37. Fuller RW, Wong DT. Serotonin reuptake blockers in vitro and in vivo. J Clin Psychopharmacol 1987; 7 (Suppl. 6): 36S–43S. 38. Furuse T, Hashimoto K. Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors. Ann Gen Psychiatry 2009; 8: 26. 39. Gatti F, Bellini L, Gasperini M et al. Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry 1996; 153 (3): 414–6. 40. Guidotti A, Costa E. Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3 alpha, 5 alpha-tetrahydroprogesterone (allopregnanolone) availability? Biol Psychiatry 1998; 44 (9): 865–73. 41. Hartter S, Wang X, Weigmann H et al. Differential effects of fluvoxamine and other antidepressants on the Biotransformation of Melatonin. J Clin Psychopharmacol 2001; 21: 167–74. 42. Hasebe S, Ago Y, Watabe Y et al. Anti-anhedonic effect of selective serotonin reuptake inhibitors with affinity for sigma-1 receptors in picrotoxin-treated mice. Br J Pharmacol 2017; 174 (4): 314–27. 43. Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol 2013; 100: 15–29. 44. Hayashi T, Tsung-Su TP. Cholesterol at the endoplasmic reticulum: roles of the sigma-1 receptor chaperone and implications thereof in human diseases. Subcell Biochem 2010; 51: 381–98. 45. Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol Clin Exp 2010; 25: 193–200. 46. Hollander E, Liebowitz MR, DeCaria C et al. Treatment of depersonalization with serotonin reuptake blockers. J Clin Psychopharmacol 1990; 10 (3): 200–3. 47. Hong WC, Yano H, Hiranita T et al. The sigma-1 receptor modulates dopamine transporter conformation and cocaine binding and may thereby potentiate cocaine self-administration in rats. J Biol Chem 2017; 292 (27): 11250–61. 48. Houck C. An open-label pilot study of fluvoxamine for mixed anxiety-depression. Psychopharmacol Bull 1998; 34 (2): 225–7. 49. Howland RH. Ketamine for the treatment of depression. J Psychosoc Nurs Ment Health Serv 2013; 51 (1): 11–4. 50. Irons J. Fluvoxamine in the treatment of anxiety disorders. Neuropsychiatr Dis Treat 2005; 1 (4): 289–99. 51. Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharmacol 2014; 727: 167–73. 52. Kasahara J, Uchida H, Tezuka K, Oka N. Postischemic Anhedonia Associated with Neurodegenerative Changes in the Hippocampal Dentate Gyrus of Rats. Neural Plast 2016; 2016: 5054275. 53. Kato T, Kajiyama S, Hamada H, Kawamoto M. Long-term administration of fluvoxamine attenuates neuropathic pain and involvement of spinal serotonin receptors in diabetic model rats. Hiroshima J Med Sci 2013; 62 (4): 83–9. 54. Keltner NL, McAfee KM, Taylor CL. Mechanism and treatment of SSRis-induced sexual dysfunction. Perspect Psychiatr Care 2002; 38: 111–6. 55. Kishimoto A, Todani A, Miura J et al. The opposite effects of fluvoxamine and sertraline in the treatment of psychotic major depression: a case report. Ann Gen Psychiatry 2010; 9: 23. 56. Korte SM, Prins J, Krajnc AM et al. The many different faces of major depression: it is time for personalized medicine. Eur J Pharmacol 2015; 753: 88–104. 57. Laws D, Ashford JJ, Anstee JA. A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. Acta Psychiatr Scand 1990; 81 (2): 185–9. 58. Leonard BE. Sigma receptors and sigma ligands: background to a pharmacological enigma. Pharmacopsychiatry 2004; 37 (Suppl. 3): S166–70. 59. Lopukhov IG. [A comparative clinical evaluation of the antidepressive activity of fluoxetine and fluvoxamine]. [Article in Russian]. Zh Nevrol Psikhiatr Im S.S.Korsakova. 1997; 97 (4): 53–7. 60. Manna V, Bolino F, Di Cicco L. Chronic tension-type headache, mood depression and serotonin: therapeutic effects of fluvoxamine and mianserine. Headache 1994; 34 (1): 44–9. 61. Maurice T, Su TP. The pharmacology of sigma-1 receptors. Pharmacol Ther 2009; 124 (2): 195–206. 62. Minaiyan M, Hajhashemi V, Rabbani M et al. Evaluation of anti-colitic effect of fluvoxamine against acetic acid-induced colitis in normal and reserpinized depressed rats. Eur J Pharmacol 2015; 746: 293–300. 63. Neylan TC, Metzler TJ, Schoenfeld FB et al. Fluvoxamine and sleep disturbances in posttraumatic stress disorder. J Trauma Stress 2001; 14: 461–7. 64. Nguyen L, Robson MJ, Healy JR et al. Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan. PLoS One 2014; 9 (2): e89985. 65. Ohyama S, Kuniyoshi M, Nishi S, Inanaga K. [Postherpetic neuralgia alleviated by an SSRI fluvoxamine: two cases of PHN accompanied with depression were treated with fluvoxamine]. [Article in Japanese]. Nihon Shinkei Seishin Yakurigaku Zasshi 2004; 24 (2): 79–81. 66. Omori IM, Watanabe N, Nakagawa A et al. Fluvoxamine versus other antidepressive agents for depression. Cochrane Database Syst Rev 2010; 3: CD006114. 67. Pae CU, Masand PS, Ajwani N et al. Irritable bowel syndrome in psychiatric perspectives: a comprehensive review. Int J Clin Pract 2007; 61 (10): 1708–18. 68. Panteleeva GP, Abramova LI, Korenev AN. [Selective serotonin reuptake inhibitors in the therapy of various types of endogenous depressions]. [Article in Russian]. Zh Nevrol Psikhiatr Im S.S.Korsakova 2000; 100 (3): 36–41. 69. Peeters M, Romieu P, Maurice T et al. Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine. Eur J Neurosci 2004; 19 (8): 2212–20. 70. Riesner HJ, Zeitler C, Schreiber H, Wild A. [Additional treatment in chronic pain syndrome due to hip and knee arthritis with the selective serotonin reuptake inhibitor fluvoxamine (Fevarin]. [Article in German]. Z Orthop Unfall 2008; 146 (6): 742–6. 71. Sato S, Kawamata T, Kobayashi T, Okada Y. Antidepressant fluvoxamine reduces cerebral infarct volume and ameliorates sensorimotor dysfunction in experimental stroke. Neuroreport 2014; 25 (10): 731–6. 72. Scarella TM, Franzen JR. Case report: Improvement in dissociative symptoms with mixed amphetamine salts. J Trauma Dissociation 2017; 18 (5): 649–62. 73. Shimodozono M, Kawahira K, Kamishita T et al. Reduction of central poststroke pain with the selective serotonin reuptake inhibitor fluvoxamine. Int J Neurosci 2002; 112 (10): 1173–81. 74. Shirayama Y, Hashimoto K. A case of psychotic depression treated with fluvoxamine monotherapy. Clin Psychopharmacol Neurosci 2010; 8: 53–4. 75. Sierra M. Depersonalization: A New Look at a Neglected Syndrome. 1st Ed. Cambridge University Press, 2012. 76. Silvestri R, Pace-Schott E, Gersh T et al. Effects of fluvoxamine and paroxetine on sleep structure in normal subjects: a home-based Nightcap evaluation during drug administration and withdrawal. J Clin Psychiatry 2001; 62: 642–52. 77. Sonawalla SB, Spillmann MK, Kolsky AR et al. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. J Clin Psychiatry 1999; 60 (9): 580–3. 78. Stahl SM. Antidepressant treatment of psychotic major depression: potential role of the sigma receptor. CNS Spectr 2005; 10 (4): 319–23. 79. Stahl SM. Selectivity of SSRIs: individualising patient care through rational treatment choices. Int J Psychiatry Clin Pract 2004; 8 (Suppl. 1): 3–10. 80. Stahl SM. Stahl's Essential Psychopharmacology. Neuroscientific Basis and Practical Application. 4th Ed. Cambridge University Press, 2013. 81. Sunami E, Usuda K, Nishiyama Y et al. A preliminary study of fluvoxamine maleate on depressive state and serum melatonin levels in patients after cerebral infarction. Intern Med 2012; 51 (10): 1187–93. 82. Svestka J, Cesková E, Rysánek R et al. [The status of fluvoxamine among the antidepressive agents]. [Article in Czech]. Cesk Psychiatr 1992; 88 (5): 209–19. 83. Tadokoro S, Kanahara N, Kikuchi S et al. Fluvoxamine may prevent onset of psychosis: a case report of a patient at ultra-high risk of psychotic disorder. Ann Gen Psychiatry 2011; 10: 26. 84. Tagashira H, Bhuiyan MS, Shioda N, Fukunaga K. Fluvoxamine rescues mitochondrial Ca2+ transport and ATP production through s1-receptor in hypertrophic cardiomyocytes. Life Sci 2014; 95 (2): 89–100. 85. Tagashira H, Bhuiyan S, Shioda N et al. s1-receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunction in mice. Am J Physiol Heart Circ Physiol 2010; 299 (5): H1535–45. 86. Tagashira H, Fukunaga K. [Cardioprotective effect of fluvoxamine, sigma-1 receptor high affinity agonist]. [Article in Japanese]. Yakugaku Zasshi 2012; 132 (2): 167–72. 87. Uzunova V, Sheline Y, Davis JM et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci U S A 1998; 95 (6): 3239–44. 88. Van den Broek WW, Birkenhäger TK, Mulder PG et al. A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology (Berl) 2004; 175 (4): 481–6. 89. Van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993; 24 (Suppl. 1): 203–9. 90. Van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1995; 29 (Suppl. 1): 1–9. 91. Von Bahr C, Ursing C, Yasui N et al. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects – an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. Eur J Clin Pharmacol 2000; 56: 123–7. 92. Westenberg HG, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract 2006; 60 (4): 482–91. 93. Wilson SJ, Bell C, Coupland NJ, Nutt DJ. Sleep Changes During Long-Term Treatment of Depression with Fluvoxamine – A Home-Based Study. Psychopharmacology 2000; 149: 360–5. 94. Zanardi R, Franchini L, Gasperini M et al. Long-term treatment of psychotic (delusional) depression with fluvoxamine: an open pilot study. Int Clin Psychopharmacol 1997; 12: 195–7. 95. Zanardi R, Franchini L, Serretti A et al. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. J Clin Psychiatry 2000; 61: 26–9. 96. Zhang CL, Feng ZJ, Liu Y et al. Methylphenidate enhances NMDA-receptor response in medial prefrontal cortex via s1 receptor: a novel mechanism for methylphenidate action. PLoS One 2012; 7 (12): e51910.